Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17347396 | 0.89 | ALDH1A1 (0.58) | USP2CYP2C9NPSR1MAPTPTGDR2 | |
| SCHEMBL17347409 | 0.87 | ALDH1A1 (0.64) | USP2CYP2C9NPSR1MAPTHTT | |
| SCHEMBL17331322 | 0.82 | CYP2C9 (0.60) | CYP2C9NPSR1HTTALDH1A1TSHR | |
| SCHEMBL17331324 | 0.78 | CYP2C9 (0.80) | CYP2C9NPSR1HTTCYP3A4CYP2D6 | |
| SCHEMBL14646991 | 0.77 | PTGDR2 (0.71) | PTGDR2 | |
| SCHEMBL24102498 | 0.77 | EGFR (0.50) | ALDH1A1KMT2AMEN1RAB9AHPGD | |
| SCHEMBL29535886 | 0.77 | EGFR (0.50) | ALDH1A1KMT2AMEN1RAB9AHPGD | |
| SCHEMBL13754043 | 0.74 | FLT1 (0.62) | USP2NPSR1HTTCYP3A4CYP2C19 | |
| SCHEMBL13753150 | 0.74 | KMT2A (0.60) | MAPTALDH1A1KDM4EKMT2AHPGD | |
| SCHEMBL17331345 | 0.74 | L3MBTL1 (0.57) | USP2NPSR1HTTALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701627-B2 | LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disorders | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-07-11 | — | — | US | disclosed |
| US-20150361038-A1 | LRRK2 GTP BINDING INHIBITORS FOR TREATMENT OF PARKINSON'S DISEASE AND NEUROINFLAMMATORY DISORDERS | UNIVERSITY OF MARYLAND, BALTIMORE | 2015-12-17 | — | — | US | disclosed |
| US-20150105438-A1 | SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361038-A1 | LRRK2 GTP BINDING INHIBITORS FOR TREATMENT OF PARKINSON'S DISEASE AND NEUROINFLAMMATORY DISORDERS | LRRK2, PARK7, SNCA | USP2 2229/4885CYP2C9 4867/4885NPSR1 3449/4885 |
| US-20150105438-A1 | SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES | QDPR, IDO1, ADRA1D | USP2 2523/4885CYP2C9 1275/4885NPSR1 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.